Table I.
Cellular immunity (M±m).
| Indices | Sample Group | Control Group | Study Group | ||
|---|---|---|---|---|---|
| 1 | 2 | 1 | 2 | ||
| LBTR – PHA % | 79.9±1.16 | 65.1±1.23• | 68.9±1.18♦ | 56.3±1.33• | 61.7±1.21♦ |
| LBTR -Ag Mbt% | 2.0±0.21 | 3.4±0.42• | 5.6±0.54♦ | 3.3±0.28• | 4.4±0.28♦ |
| T-lymphocytes % | 60.2±0.75 | 63.3±1.24• | 68.5±1.52♦ | 52.2±0.94• | 56.6±0.78♦ |
| Th-lymphocytes % | 43.7±0.85 | 42.3±1.20 | 44.1±1.39 | 34.1±0.81• | 36.7±0.73♦ |
| Ts- lymphocytes % | 16.6±0.72 | 20.9±0.83• | 24.4±1.23♦ | 18.1±0.64 | 19.8±0.55♦ |
| B-lymphocytes % | 24.9±0.70 | 26.8±0.34• | 23.5±0.51♦ | 28.8±0.71• | 26.1±0.58♦ |
Legend:
•
- statistical difference in comparison with healthy group individuals;
♦
- statistical difference in comparison with healthy group individuals; losis treatment was lower in
LBTR – PHA lymphocyte blast transformation reaction induced by phytohemagglutinin;
LBTR -Ag Mbt - lymphocyte blast transformation reaction induced by mycobacterial antigens;
Th-lymphocytes - helper T (CD4+) lymphocytes;
Ts-lymphocytes suppressor (CD8+) lymphocytes.